Refer to a friend 2009-11-09 23:40:04 - days following the presentation. About Biogen Idec Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Full Article at PR-Inside.com

Calls have been the option of choice lately on Biogen Idec Inc. (BIIB: sentiment, chart, options). Full Article at SchaeffersResearch.com

Today Asher Mullard Elan and Biogen Idec have updated the US label of their multiple sclerosis drug Tysabri (natalizumab) to re-emphasise that it carries a risk of inducing the rare, but potentially fatal, brain infection progressive... Full Article at Scrip News

As expected, Biogen Idec and Elan have amended the label of their multiple sclerosis med Tysabri. Full Article at FiercePharma

09 November 2009 Elan Corp and partner Biogen Idec have made changes to the label on Tysabri to reflect the increased risk of a rare and potentially fatal brain disease when the multiple sclerosis blockbuster is taken over a... Full Article at PharmaTimes

NEW YORK - A brain infection linked to Biogen Idec Inc. and Elan Corp.’s Tysabri is more likely to occur the longer patients use the multiple sclerosis drug, new prescribing information says. Full Article at Boston Globe